TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Kidney transplant recipients at Washington University/Barnes-Jewish Hospital~2. Experiencing GI toxicity from MPA as determined by the treating physician within 12 months post-renal transplant~3. On standard immunosuppression with tacrolimus and prednisone~Exclusion Criteria:~1. Dual organ or kidney after another solid organ transplant~2. Presence of a preexisting significant GI condition that does not have a presumed causal relationship with MPA~3. Evidence of any GI disorder induced by an infection, underlying medical condition, or concomitant medication other than MPA~4. Estimated glomerular filtration rate (eGFR) \<40 ml/min at time of possible conversion~5. Proteinuria \>1 gram/day at time of possible conversion~6. Profound bone marrow suppression at the time of possible conversion as defined as:~   * Hemoglobin \<10 g/dL~  * White blood cell (WBC) \< 3 K/cumm~  * Platelets \<100 K/cumm~7. Wound healing issues at time of possible conversion (eg, wound dehiscence, wound infection, incisional hernia, lymphocele, seroma)~8. Elevated total cholesterol (\>350 mg/dL) and/or triglycerides (\>500 ng/dL) at time of possible conversion~9. Hypersensitivity to everolimus, sirolimus, or other rapamycin derivatives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interventional (EVR) (Type: ACTIVE_COMPARATOR): Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus
- Prior Agent (MPA) (Type: ACTIVE_COMPARATOR): Patient will have baseline data collected while on MPA for comparison with EVR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EpiCeram for Skin Protection in Healthcare Workers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. HCW using PPE at least 6 hours/day, 4 days/week or, depending on shift work, 24 hours/week, for at least one (1) month~2. Men or women, any age~3. Overall skin irritation score of at least 4 on 0-10 scale where 0 = none and 10 = worst~4. Willing to stop use of any other emollient and lotion for one (1) week between screening and baseline visit and for the duration of the study.~5. Participant is willing to stop use of or not begin use of any topical corticosteroids, emollients and lotions to the hands and face for the duration of the trial.~Exclusion Criteria:~1. History of any skin disorder existing prior to March 1, 2020 characterized by chronic visible lesions or skin irritation symptoms including, but not limited to atopic dermatitis, eczema, moderate-severe acne, chronic dry skin and psoriasis.~2. Use of topical corticosteroids within one (1) month of baseline visit.~3. History of any significant medical condition that, in the opinion of the investigator, might put the subject at risk in this trial.~4. Participation in another clinical trial within 30 days or 5 half-lives of the study agent, whichever is longer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EpiCeram (Type: EXPERIMENTAL): Open-Label, 3 (three) times per day, topical, to hands and face, for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Primary Percutaneous Pericardiotomy for Malignant Pericardial Effusion (PMAP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with confirmed active malignancy AND,~* Presence of at least moderate (\>10cm) pericardial effusion on CT or Echocardiography~Exclusion Criteria:~* Patients unable to give an informed consent,~* Previous history of open-heart surgery~* Previous history of pericardial window or pericardial instillation of sclerosing therapy.~* Scheduled thoracic or cardiac surgery within the next 3 months~* Patients with contraindications for endovascular procedure such as disseminated intravascular coagulopathy or significant ongoing bleeding tendency, and systemic septicaemia.~* Patient with small or loculated pericardial effusion that is not accessible by subxiphoid approach.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (pericardiotomy) (Type: EXPERIMENTAL): * Patient in this arm will receive balloon pericardiotomy before insertion of pericardiocentesis.~* An 20mm over-the-wire ultra-non-compliant Percutaneous Transluminal Angioplasty Balloon is used to dilate the pericardium.~* Success of balloon pericardiotomy is confirmed by full inflation of the balloon which is confirmed on two orthogonal projections.~* Standard pericardiocentesis with prolonged drainage is performed afterwards.~* Pericardial drain is removed when output is less than 100cc/day
- Control (standard pericardiocentesis) (Type: NO_INTERVENTION): * Standard pericardiocentesis procedure is performed using standard pigtail pericardial drain. - Pericardial fluid is then tapped until dry on table.~* Pericardial drain is removed when output is less than 100cc/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Exparel to Bupivacaine With Dexamethasone in TAP Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients undergoing scheduled abdominal surgery at Emory University Hospital or Emory University Hospital Midtown~* Patients willing and able to provide written informed consent~Exclusion Criteria:~* Patients less than 18 years of age, since Exparel has not been studied in this age group~* Patients who are pregnant or lactating, since Exparel has not been shown to be safe in this population, and because of potential drug transfer to child~* Patients with uncontrolled diabetes since dexamethasone may cause hyperglycemia~* Patients with liver dysfunction, since bupivacaine is hepatically metabolized~* Patients with renal failure, since bupivacaine is renally excreted, defined as requiring hemodialysis or renal replacement therapy~* Patients with allergy to one of the study drugs~* Patients with local infection, which may be exacerbated by dexamethasone~* Patients with significant opioid tolerance, defined as taking at least 60 mg oral morphine per day, 3 mg oral oxycodone per day, 25 mcg/hr fentanyl patch, 25 mg oral oxymorphone per day, 8 mg of oral hydromorphone per day or an equianalgesic dose of another opioid for one week or longer~* Patients with known coagulopathy, since bleeding risk is higher Patients who are getting neuraxial anesthesia for surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1-Exparel (Type: ACTIVE_COMPARATOR): Bupivacaine Extended-Release Liposome Injection (Exparel)will be administered via TAP block procedure
- Group 2-Bupivacaine and Dexamethasone IV (Type: ACTIVE_COMPARATOR): Bupivacaine and Dexamethasone Injection will be administered via TAP block procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients~The following patients are candidates for receiving PBZ for HFLPP. These include:~1. All patients under 16 kg.~2. Those patients between 16-18 kg whose pre bypass hemoglobin is \<16 g/dl~3. All patients are less than 18 years of age~Exclusion Criteria:~1. Those with bloodless prime in Cardiopulmonary bypass circuit~2. Age \> 18years~3. Wt. \>16 kg

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Treatment Group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study About the Effect of Doxycycline and Acetylcystein in the Treatment of CD-associated Fistulae

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* fistulizing CD~* CD \< 6 months~* at least one insufficient fistula closure try~Exclusion criteria:~* CDAI \> 200~* Abscesses~* CRP \> 100

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed stage IIIA/B NSCLC (excluding pleural effusion and mixed pathology)~2. Irresectable disease (as assessed by multidisciplinary team) or patient refusing surgery~3. Disease which can be encompassed within a radical radiotherapy treatment plan in keeping with standard practice at the participating center~4. Proposed treatment consists of radiotherapy alone or concurrent chemoradiation~5. WHO performance status 0 or 1~6. Adequate respiratory function: FEV1 ≥ 1.5 L and DLCO \> 40%, predicted on baseline pulmonary function tests~7. Age ≥ 18 years, no upper age limit~8. Estimated life expectancy of more than 6 months~9. Patient is available for follow-up~10. Written informed consent obtained~Exclusion Criteria:~1. Clinically diagnosed NSCLC~2. Previous or current malignant disease likely to interfere with the protocol treatment or comparisons~3. Prior thoracic radiotherapy~4. Proposed treatment consist of sequential chemoradiation~5. Prior lobectomy / pneumonectomy~6. Prior chemotherapy using gemcitabine or bleomycine~7. Superior sulcus tumors if the brachial plexus is within the high-dose volume~8. Medically unstable (e.g., ischaemic heart disease, esophageal disorders)~9. Pregnancy~10. Connective tissue disorders~11. Abnormal kidney function interfering with administration of iv contrast agent (GFR\<60)~12. Uncontrolled diabetes mellitus hampering 18FDG-PET~13. Inability to comply with protocol or trial procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Individualized dose escalation (Type: EXPERIMENTAL): Individualized dose escalation on the basis of the dose to the organs at risk.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Woman or man ≥ 18 Years old, histologically proven metastatic clear cell (or al least clear cell predominant) RCC,~* Good or intermediate risk according to MSKCC-criteria, Subjects falling into conditions for reimbursement of sunitinib or pazopanib in the context of mRCC,~* Measurable disease based on RECIST criteria (version 1.1) , Subject has given voluntary written informed consent,~* Subject is in the investigator's opinion, willing and able to comply with the protocol requirements, Subject has an ECOG ≤ 2,~* Subject with a life expectancy ≥ 3 months,~* Concurrent treatment with bisphosphonates and denosumab is allowed however it should have been started before screening of the study. If possible starting new medications between the baseline metabolo- and lipidomotype- and the first metabolo- and lipidomotypeanalysis should be avoided,~* Subjects having recovered from side effects from previous therapies to a grade 1 CTC vs 4.0 criteria~Exclusion Criteria:~* Patients with non-clear cell RCC and/or with sarcomatoid differentiation,~* Patients presenting any other type of cancer disease within 5 years from inclusion into this study; in the absence of cervical cancer or basocellular carcinoma, Patients with uncontrolled arterial hypertension,~* Patients with uncontrolled hypo- or hyperthyroidism,~* Patient had major surgery within 4 weeks before enrolment,~* Patient with myocardial infarction within 6 months prior enrolment or with NHYA class III otr IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia or electrocardiographic evidence of acute ischemia or active conduction system abnormalities,~* Patient has another serious medical condition that could potentially interfere with the completion of study,~* Sero-positive for HIV, Subject known to be hepatitis B surface antigen positive or who has an active hepatitis C infection,~* Subject has an active systemic infection requiring treatment,~* Female subject is pregnant or breast feeding, Subject enrolled in another clinical trial and/or receiving an investigational agent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients with sunitinib or pazopanib (Type: EXPERIMENTAL): This will be a non-randomized, proof-of-concept, prospective, longitudinal, multi-center study in patients with metastatic clear cell renal cell carcinoma with good or intermediate risk (based on MSKCC criteria) treated with sunitinib or pazopanib in first line.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stomach Intestinal Pylorus-Sparing Bariatric Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-89~* Primary: Satisfies established NIH criteria for bariatric surgery~* Revision of sleeve gastrectomy: Sleeve gastrectomy performed at least two years prior but the patient did not reach 50% excess weight loss (EWL), has regained 20% of EWL since sleeve gastrectomy, or has current BMI \> 40~* Willing and able to provide his/her own consent for the surgery~Exclusion Criteria:~* Contraindication to bariatric surgery~* Current pregnancy/breast feeding or plans for pregnancy~* Prisoners~* Previous history of gastrectomy other than sleeve gastrectomy for weight loss~* History of small bowel resection~* History of any kind of surgery to treat gastroesophageal reflux disease (GERD)~* History of or current Barrett's esophagus~* History of or any kind of cancer diagnosis in last 5 years~* Large hiatal hernia \> 5 cm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- Stomach Intestinal Pylorus Sparing (SIPS) (Type: EXPERIMENTAL): Patients undergoing SIPS procedure as their bariatric surgery of choice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Asymptomatic Congenital CMV Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Parent(s)/legal guardian(s) have signed informed consent documents\*~* Confirmation of cytomegalovirus (CMV) by urine polymerase chain reaction (PCR) testing~* Infant \</= 30 days of age at initiation of study drug~* Weight at study enrollment \>/= 1775 grams~* Gestational age \>/= 32 weeks at birth~  * There is a screening informed consent for screening phase of study participation, and a treatment informed consent for treatment phase of study participation.~Exclusion Criteria:~* Symptomatic congenital cytomegalovirus (CMV) disease\*~* Sensorineural hearing deficits as detected by formal brainstem evoked response (not a screening auditory brainstem response (abr)) of known etiology other than CMV~* Prior or current receipt of ganciclovir, valganciclovir, foscarnet, cidofovir, brincidofovir, maribavir, or letermovir~* Maternal receipt of CMV hyperimmune globulin during pregnancy~* Breastfeeding from mother who is receiving ganciclovir, valganciclovir, foscarnet, cidofovir, brincidofovir, maribavir, or letermovir~* Gastrointestinal abnormality which might preclude absorption of an oral medication (e.g., a history of necrotizing enterocolitis)~* Infants known to be born to women who are HIV positive (HIV testing is not required for study entry)~* Current receipt of other investigational drugs~  * Symptomatic disease is defined as one or more of the following: 1) thrombocytopenia, if known; 2) petechiae; 3) hepatomegaly; 4) splenomegaly; 5) intrauterine growth restriction; 6) hepatitis (elevated transaminases and/or direct bilirubin), if known; 7) central nervous system involvement of the CMV disease (such as microcephaly; radiographic abnormalities indicative of CMV CNS disease, if known; abnormal CSF indices for age, if known; chorioretinitis, if known; and/or positive CMV PCR from CSF, if known).

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 30 Days
- Healthy Volunteers: f

Study Arms:
- Confirmed congenital CMV without baseline SNHL (Type: EXPERIMENTAL): Valganciclovir 16 mg/kg/dose orally twice daily for four months, n=229

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Improving Neurological Outcome for Acute Basilar Artery Occlusion With Sufficient Recanalization After Thrombectomy by Intraarterial Tenecteplase (INSIST-IT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Patients with basilar artery occlusion who received endovascular treatment within 24 hours of estimated time of stroke onset as per BASICS trial definition;~* National Institute of Health Stroke Scale (NIHSS) ≥ 6 before endovascular treatment;~* Successful recanalization (mTICI 2b-3) after endovascular treatment;~* PC-ASPECTS ≥ 6 on CT;~* Absence of parenchymal hematoma on CT images done in the angio suite immediately after the procedure;~* Modified Rankin Scale score before stroke onset ≤ 3;~* Signed informed consent by patient or their legally authorized representative.~Exclusion Criteria:~* baseline PC ASPECTS \< 5 on CT;~* More than six retrieval attempts in the same vessel;~* Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage;~* Coagulation disorders, systemic hemorrhagic diathesis, thrombocytopenia (\<100000/mm3), or INR \> 1.7;~* Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;~* After recanalization, severe and sustained (i.e., \> 5 minutes) uncontrolled hypertension (systolic blood pressure over 180mmHg or diastolic blood pressure over 105 mmHg) refractory to antihypertensive medication;~* Patients with contraindication or allergic to any ingredient of drugs in our study~* Pregnancy, plan to get pregnant or during lactation~* The estimated life expectancy is less than 6 months due to other serious diseases;~* Other conditions unsuitable for this clinical study assessed by researcher.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TNK group (Type: EXPERIMENTAL): None
- control group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy